Calogero D’Alessandria

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

Matthias Heck, Robert Tauber, Sebastian Schwaiger et al. · European Urology · 2018 · 308 citations

Medicine, Nuclear Medicine, Oncology +17

Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA

Benedikt Feuerecker, Robert Tauber, Karina Knorr et al. · European Urology · 2020 · 267 citations

Medicine, Oncology, Pharmacology +14

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Andrei Gafita, Jérémie Calais, Tristan Grogan et al. · The Lancet Oncology · 2021 · 246 citations · Full text

Medicine, Oncology, Urology +17

PET of CXCR4 Expression by a ⁶⁸Ga-Labeled Highly Specific Targeted Contrast Agent

Eleni Gourni, Oliver Demmer, Margret Schottelius et al. · Journal of Nuclear Medicine · 2011 · 222 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Radiation Dosimetry for¹⁷⁷Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions

Shozo Okamoto, Anne Thieme, Jakob Allmann et al. · Journal of Nuclear Medicine · 2016 · 216 citations · Full text

Medicine, Nuclear Medicine, Oncology +17